Undertaking and Scope. Each Party agrees to use Commercially Reasonable and Diligent Efforts to perform its activities detailed in the Development Plans in a professional and timely manner.
Undertaking and Scope. From time to time the Research Management Committee will agree on the general direction of the research to be performed hereunder. The correspondence and other material documenting such agreement are collectively referred to herein as the “Research Plan.” Each party agrees to use its best efforts to perform the activities detailed in the Research Plan, in a professional and timely manner. Onyx agrees to use its best efforts at its cost [*] to (i) develop and transfer to Warner [*] screening assays [*] of the Term of the Research Collaboration for specific targets in the Field selected by the Research Management Committee, (ii) supply protein required to run such screens and (iii) provide for the testing of substantially all of Onyx’s compound library in such screens. Onyx shall not knowingly provide or perform research on any compounds the use of which would require a royalty or other payment to any third party, unless the Research Management Committee agrees that such compound should be provided and the parties agree in writing how such royalty or other payment will be paid. Warner agrees to use its best efforts at its cost (including the cost of any royalties or other amounts payable by Warner to third parties) to (i) screen substantially all of its compound library with such screens provided by Onyx and (ii) conduct medicinal chemistry and animal pharmacology as the Research Management Committee deems appropriate. Promptly after the Effective Date, Onyx and Warner will disclose to each other all information possessed by it relevant to the Field and necessary or helpful to perform the work described in the Research Plan (except to the extent precluded by the pre-existing confidentiality obligations described on Schedule 1 hereto). During the Term of the Research Collaboration, or one year thereafter, the Research Management Committee and either party individually may from time to time declare any compound that meets the definition therefor in Article 1 to be a Collaboration Compound. Notwithstanding the foregoing, neither party will be required to offer the other party any compounds or information relating to compounds that have been identified as candidates for cGLP/cGMP studies on or before the Effective Date, or are hereafter so identified without material application of information provided by the other party or developed pursuant to the Collaboration. Neither party shall be required to screen under this Collaboration or to offer to the other party a...
Undertaking and Scope. During the first 30 days after the Effective Date, the parties shall work together to develop a plan for the creation and use of the Research Database (a "Research Plan") by the parties. The Research Management Committee will review and approve or modify the general direction of such Research Plan. The Research Plan shall include such correspondence and other material of the parties documenting the parties' work to create the Research Database. At least 90 days before each anniversary of the Effective Date during the Research Term, the parties shall propose to the RMC a Research Plan for the subsequent year's work under the Research Program. The RMC shall review, modify, if appropriate, and amend the Research Plan. Each party agrees to use all reasonable efforts to perform the activities detailed in the Research Plan, in a professional and timely manner.
Undertaking and Scope. (a) Prior to the earlier of (i) the initial meeting of the Research Management Committee and (ii) in the case of Indication #1, 30 days from the Agreement Date, or in the case of the other Indications, 30 days from the date that the applicable option under Section 6 is exercised by JT, the parties shall work together to agree upon a plan for the creation and use of the Research Databases by the parties for the first year of the Research Program. Such plan shall set forth the schedule of specific activities to be undertaken during the applicable period of the Program Term, the resources to be employed, including the allocation of Scientific FTEs and each scientist's role, the intended acquisition of Samples during such period (and the timing thereof) and the budget for such period. The Research Management Committee will review and, in its discretion, approve or modify the general direction of such plan. Such plan, as approved by the RMC for any year of the Research Program, is referred to herein as the "Research Plan." A timeline of the research to be performed under the Research Plan for Indication #1 and the related staff allocation plan is attached to this Agreement as Schedule 2.1 for reference purposes. At least 90 days before each anniversary of the Effective Date during the Program Term, the parties shall propose to the RMC a Research Plan to govern the further development of the Research Databases during the following year of the Research Program, and the RMC shall review, modify if appropriate, and
Undertaking and Scope. Each party agrees to use its best efforts to perform the activities detailed in the Stage 1 Research Plan attached hereto as Exhibit 1 in a professional and timely manner. Durixx Xxxxx 0, XxxxxXxxx xxxl use its best efforts at its cost (including the cost of any royalties or other amounts owed to third parties by LeukoSite) to develop and transfer to Warner (i) a receptor-ligand screen for MCP-1 Inhibitors, and (ii) an MCP-1 triggered cell based screen for MCP-1
Undertaking and Scope. Each party agrees to use its best efforts to perform the activities detailed in the Stage I Research Plan attached hereto as Exhibit 1 in a professional and timely manner. Durixx Xxxxx 0, XxxxxXxxx xxxl use its best efforts at its cost (including the cost of any royalties or other amounts owed to third parties by LeukoSite) to develop and transfer to Warner a receptor-ligand screen for IL-8 Inhibitors and (ii) cells containing an IL-8 receptor useful in creating an IL-8 triggered cell based screen for IL-8
Undertaking and Scope. Each party agrees to use its best efforts to perform the activities detailed in the research plan attached hereto as Exhibit 1 (the "Research Plan") in a professional and timely manner. Each party agrees to use its best efforts to assure the complete and prompt exchange of Background Technology, Collaboration Technology, and the results of all activities conducted pursuant to the Research Plan. During the term of the Collaboration, (i) Warner will use its best efforts, at its cost (including the cost of any royalties or other amounts owed to third parties by Warner) to screen substantially all of its compound library with such screen provided by LeukoSite and (ii) LeukoSite will use its best efforts, at its cost (including the cost of any royalties or other amounts owed to third parties by LeukoSite) to screen substantially all of its compound library with the same screen that it provides to Warner for such purposes. Pursuant to the Research Plan, LeukoSite and Warner will use their best efforts, each at its own cost, to conduct in vitro and in vivo characterization of the compounds identified as Integrin Antagonists in such screen.
Undertaking and Scope. During the 45 days after the Agreement Date, Organon will work to develop a plan for the creation and use of the Research Database, with input as appropriate from Gene Logic. The RMC will review and, in its discretion, approve or modify the general direction of such plan. Such plan, as approved by the RMC for any year of the Research Program, is referred to herein as the "Research Plan." During the Research Term, at least 30 days before each of February 27, 2000 and 2001, Organon will propose to the RMC a Research Plan for the periods from February 27, 2000 to February 27, 2001 and from February 27, 2001 to *CONFIDENTIAL TREATMENT REQUESTED
Undertaking and Scope. The Research Management Committee will agree on and, in its discretion, modify the general direction of the Research Program to be performed under this Section 2. Correspondence and other material documenting such agreement and approved by the RMC are collectively referred to herein as the Research Plan. Initially, the Research Plan shall be as set forth on Schedule 2.1 which is attached hereto and incorporated herein by reference. Each party agrees to use its best efforts to perform the activities detailed in the Research Plan, in a professional and timely manner. Promptly after the Effective Date and, in the case of AMPA Antagonists, the Restatement Date, each party shall disclose to the other all Background Technology and Collaboration Technology then possessed by it relevant to the Field and necessary or helpful to perform the work described in the Research Plan. Notwithstanding the foregoing, Warner shall not be obligated to disclose to CoCensys the structure of any compound existing in the Warner Background Technology or Collaboration Technology until NRSSA or AMPA Antagonist activity is confirmed in such compound and CoCensys shall not be obligated to disclose to Warner the structure of any compound existing in the CoCensys Background Technology or Collaboration Technology until NRSSA or AMPA Antagonist activity is confirmed in such compound. Each party shall also provide to the other samples of compounds and biological materials that comprise its Background Technology or Collaboration Technology to the extent necessary for such other party to perform its obligations under the Research Plan and to the extent owned or Controlled by such party, provided, however, that neither party shall be obligated to unreasonably deplete its compound library. CoCensys acknowledges that, as of the Effective Date, it is in possession of certain [*], which were provided by a Third Party. CoCensys will use reasonable efforts to obtain permission from such Third Party to share such [*] with Warner.
Undertaking and Scope. During the period commencing on the Agreement Date and ending on August 15, 1998, AgrEvo and Gene Logic will work to develop a plan for the creation and use of the Research Database. The RMC will review and, in its discretion, approve or modify the general direction of such plan. Such plan, as approved by the RMC for any year of the Research Program, is referred to herein as the "Research Plan." The primary deliverables for the Research Program are set forth in Schedule 2.1 attached hereto. At least 120 days before each anniversary of the Effective Date during the Research Term, AgrEvo and Gene Logic will jointly develop and propose to the RMC a Research Plan to govern further development of the Research Database during the following year of the Research Program, with input as appropriate from Gene Logic, and the RMC shall review, modify if appropriate, and approve such Research Plan by the date 90 days before such anniversary. At any time, the RMC may modify or amend any such Research Plan as appropriate or necessary to reflect the parties' experiences in performing the Research Program. Each party agrees to use all reasonable efforts to perform the activities detailed in the Research Plan in a professional and timely manner.
